Meeting
2023 ASCO Annual Meeting
Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.
Authors
Federica Marmorino
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
Federica Marmorino , Gianmarco Piccinno , Daniele Rossini , Filippo Ghelardi , Sabina Murgioni , Lisa Salvatore , Vincenzo Nasca , Carlotta Antoniotti , Francesca Daniel , Francesco Schietroma , Veronica Conca , Carolina Alves Costa Silva , Emiliano Tamburini , Stefano Tamberi , Alessandro Passardi , Lorenzo Antonuzzo , Raffaella D'Onofrio , Laurence Zitvogel , Chiara Cremolini , Lisa Derosa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Epidemiology/Outcomes
Clinical Trial Registration Number
NCT03721653
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3534)
DOI
10.1200/JCO.2023.41.16_suppl.3534
Abstract #
3534
Poster Bd #
234
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study.
First Author: Alessandra Boccaccino
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Bevacizumab combined with atezolizumab or sintilimab as second-line treatment in patients with advanced hepatocellular carcinoma: A retrospective study.
First Author: Leijuan Gan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting.
First Author: Bahar Saberzadeh Ardestani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
First Author: Alina Pascale